Suppliers / Sanofi

Sanofi

France 179 employees 3 duplicate records merged Updated 9 July 2026

Sanofi is an API and finished-dose manufacturer based in France. It appears in 5,134 regulatory filings across 40 regulators, without an active US DMF or CEP on file. Its filings concentrate with INHRR (VE), AEMPS (ES) and Health Canada. Its GMP standing is certified by ANSM (FR), ZLG (DE) and NAFDAC (NG), among 9 authorities. Its most recent recorded inspection, by US FDA, closed on 25 March 2022 as VAI. Customs aggregates show $284 of exports covering 6 molecules to 1 destination in 2022.

0
active US DMFs
0
valid CEPs
12
registered plants 1 with an FDA FEI number
5,134
filings across 40 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 25 March 2022 VAI US FDA
  • 14 May 2019 VAI US FDA
  • 3 March 2017 VAI US FDA
  • 26 June 2015 VAI US FDA
  • 5 December 2013 NAI US FDA
  • 2 July 2013 VAI US FDA
  • 30 April 2012 NAI US FDA
  • 14 July 2011 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
17404 Riells I Viabrea (Girona), United Arab Emirates Not on file
Riells i Viabrea (Girona), United Arab Emirates Not on file
Frankfurt am Main, United Arab Emirates Not on file
Vernier, Switzerland Not on file
Vernier, Switzerland Not on file
Frankfurt am Main, Germany Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Cabazitaxel SFDA (Saudi Arabia) 1
Fexofenadine SFDA (Saudi Arabia) 1
Glimepiride SFDA (Saudi Arabia) 1
Methylprednisolone As Methylprednisolone Hemisuccinate SFDA (Saudi Arabia) 1
Ramipril SFDA (Saudi Arabia) 1
Teriflunomide SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Albendazole finished dose Alprazolam finished dose Ambroxol finished dose Ampicillin finished dose Atovaquone finished dose Benzocaine finished dose Betahistine finished dose Bisacodyl finished dose Bromhexine finished dose Capecitabine finished dose Carbamazepine finished dose Carbocisteine finished dose
Show 59 more molecule pages
Cefixime finished dose Chlorthalidone finished dose Ciclopirox finished dose Clonazepam finished dose Codeine finished dose Desloratadine finished dose Dexamethasone finished dose Diazepam finished dose Digoxin finished dose Diltiazem finished dose Diphenhydramine finished dose Domperidone finished dose Escitalopram finished dose Ezetimibe finished dose Fexofenadine API Fluconazole finished dose Furosemide finished dose Gentamicin finished dose Glibenclamide finished dose Glimepiride API Guaifenesin finished dose Hydrochlorothiazide finished dose Ibandronic Acid finished dose Lamotrigine finished dose Levofloxacin finished dose Lisinopril finished dose Loratadine finished dose Mebendazole finished dose Mefenamic Acid finished dose Meloxicam finished dose Metoclopramide finished dose Metronidazole finished dose Mirtazapine finished dose Montelukast finished dose Nystatin finished dose Ofloxacin finished dose Omeprazole finished dose Oxybutynin finished dose Paracetamol finished dose Paroxetine finished dose Phenobarbital finished dose Prednisone finished dose Pseudoephedrine finished dose Quetiapine finished dose Ramipril API Rifampicin finished dose Rosuvastatin finished dose Roxithromycin finished dose Tetracycline finished dose Trazodone finished dose Triamcinolone finished dose Triamcinolone Acetonide finished dose Trimetazidine finished dose Ursodeoxycholic Acid finished dose Valproic Acid finished dose Valsartan finished dose Venlafaxine finished dose Verapamil finished dose Vigabatrin finished dose

Filings and GMP by regulator

Regulator Filings GMP certificates
INHRR (VE) 769 None
AEMPS (ES) 607 1
Health Canada 478 None
MEDSAFE (NZ) 423 None
INFARMED (PT) 272 None
AIFA (IT) 271 None
ANSM (FR) None 22
ZLG (DE) None 6
NAFDAC (NG) None 5
EMA None 5
EAEU_EEC None 3
ANVISA (Brazil) None 2
DRAP (PK) None 1
EDA (EG) None 1

Scale

Year Revenue Exports Destinations
2024 $78.5M Not reported Not reported
2022 $920.0B $284 1

Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.

Comparing suppliers?

Choose your molecules and target markets. Sanofi comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 25 March 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts
Company filings
Revenue as reported